Browse > Article
http://dx.doi.org/10.3345/kjp.2013.56.2.75

Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease  

Park, Hyo Min (Department of Pediatrics, Kyungpook National University School of Medicine)
Lee, Dong Won (Department of Pediatrics, Daegu Fatima Hospital)
Hyun, Myung Chul (Department of Pediatrics, Kyungpook National University School of Medicine)
Lee, Sang Bum (Department of Pediatrics, Kyungpook National University School of Medicine)
Publication Information
Clinical and Experimental Pediatrics / v.56, no.2, 2013 , pp. 75-79 More about this Journal
Abstract
Purpose: It has been reported that 10% to 20% of children with Kawasaki disease (KD) will not respond to intravenous immunoglobulin (IVIG) treatment. In this study, we aimed to identify useful predictors of therapeutic failure in children with KD. Methods: We examined 309 children diagnosed with KD at the Kyungpook National University Hospital and the Inje University Busan Paik Hospital between January 2005 and June 2011. We retrospectively reviewed their medical records and analyzed multiple parameters in responders and nonresponders to IVIG. Results: Among the 309 children, 30 (9.7%) did not respond to IVIG. They had significantly higher proportion of neutrophils, and higher levels of aspartate aminotransferase, alanine aminotransferase (ALT), total bilirubin, and N-terminal fragment of B-type natriuretic peptide than did responders. IVIG-nonresponders had a significantly longer duration of hospitalization, and more frequently experienced coronary artery lesion, and sterile pyuria. No differences in the duration of fever at initial treatment or, clinical features were noted. Conclusion: Two independent predictors (ALT${\geq}$84 IU/L, total bilirubin${\geq}$0.9 mg/dL) for nonresponse were confirmed through multivariate logistic regression analysis. Thus elevated ALT and total bilirubin levels might be useful in predicting nonresponse to IVIG therapy in children with KD.
Keywords
Kawasaki disease; Intravenous immunoglobulin; Predictor; Alanine aminotransferase; Total bilirubin;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12.   DOI   ScienceOn
2 Ashouri N, Takahashi M, Dorey F, Mason W. Risk factors for nonresponse to therapy in Kawasaki disease. J Pediatr 2008;153: 365-8.   DOI   ScienceOn
3 Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gamma- globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007;166:131-7.
4 Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149:237-40.   DOI   ScienceOn
5 Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008;153:117-21.   DOI   ScienceOn
6 Do YS, Kim KW, Chun JK, Cha BH, Namgoong MK, Lee HY. Predicting factors for refractory Kawasaki disease. Korean Circ J 2010; 40:239-42.   DOI   ScienceOn
7 Chiang AN, Hwang B, Shaw GC, Lee BC, Lu JH, Meng CC, et al. Changes in plasma levels of lipids and lipoprotein composition in patients with Kawasaki disease. Clin Chim Acta 1997;260:15-26.   DOI   ScienceOn
8 Kuo HC, Liang CD, Wang CL, Yu HR, Hwang KP, Yang KD. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease. Acta Paediatr 2010;99:1578-83.   DOI   ScienceOn
9 Watanabe T, Abe Y, Sato S, Uehara Y, Ikeno K, Abe T. Hyponatremia in Kawasaki disease. Pediatr Nephrol 2006;21:778-81.   DOI   ScienceOn
10 Watanabe T, Abe Y, Sato S, Uehara Y, Ikeno K, Abe T. Sterile pyuria in patients with Kawasaki disease originates from both the urethra and the kidney. Pediatr Nephrol 2007;22:987-91.   DOI
11 Newburger JW, Burns JC, Beiser AS, Loscalzo J. Altered lipid profile after Kawasaki syndrome. Circulation 1991;84:625-31.   DOI   ScienceOn
12 Yun SW, Lee HS, Kim DW, Rhee KW, Jung YS. Changes of lipid and lipoprotein compositions in Kawasaki disease and its impact on cardiac complications. Korean J Pediatr 2005;48:1370-7.
13 Davis GK, Bamforth F, Sarpal A, Dicke F, Rabi Y, Lyon ME. B-type natriuretic peptide in pediatrics. Clin Biochem 2006;39:600-5.   DOI   ScienceOn
14 Hall C. NT-ProBNP: the mechanism behind the marker. J Card Fail 2005;11(5 Suppl):S81-3.   DOI   ScienceOn
15 Newton PJ, Betihavas V, Macdonald P. The role of B-type natriuretic peptide in heart failure management. Aust Crit Care 2009; 22:117-23.   DOI   ScienceOn
16 Sullivan DR, West M, Jeremy R. Utility of brain natriuretic peptide (BNP) measurement in cardiovascular disease. Heart Lung Circ 2005;14:78-84.   DOI   ScienceOn
17 Dahdah N, Siles A, Fournier A, Cousineau J, Delvin E, Saint-Cyr C, et al. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol 2009;30:810-7.   DOI   ScienceOn
18 Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L, et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009;30:3-8.   DOI   ScienceOn
19 Nasser N, Bar-Oz B, Nir A. Natriuretic peptides and heart disease in infants and children. J Pediatr 2005;147:248-53.   DOI   ScienceOn
20 Nir A, Nasser N. Clinical value of NT-ProBNP and BNP in pediatric cardiology. J Card Fail 2005;11(5 Suppl):S76-80.   DOI   ScienceOn
21 Kawamura T, Wago M, Kawaguchi H, Tahara M, Yuge M. Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int 2000;42:241-8.   DOI   ScienceOn
22 Harnden A, Takahashi M, Burgner D. Kawasaki disease. BMJ 2009;338:b1514.   DOI
23 Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33.   DOI   ScienceOn
24 Royle J, Burgner D, Curtis N. The diagnosis and management of Kawasaki disease. J Paediatr Child Health 2005;41:87-93.   DOI   ScienceOn
25 Rowley AH, Shulman ST. Pathogenesis and management of Kawasaki disease. Expert Rev Anti Infect Ther 2010;8:197-203.   DOI   ScienceOn
26 Shulman ST, Rowley AH. Advances in Kawasaki disease. Eur J Pediatr 2004;163:285-91.   DOI   ScienceOn